Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 9/20 | 0.53 |
| ▸ | CCR2 | P41597 | 3/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29483303 | 0.87 | NPBWR1 (0.52) | NPBWR1MCHR1CMA1CYP19A1UCHL1 | |
| SCHEMBL6603633 | 0.87 | NPBWR1 (0.52) | NPBWR1MCHR1UCHL1 | |
| SCHEMBL4680080 | 0.84 | NPBWR1 (0.47) | NPBWR1CCR2MCHR1CYP19A1UCHL1 | |
| SCHEMBL8886643 | 0.84 | NPBWR1 (0.51) | NPBWR1MCHR1CMA1 | |
| SCHEMBL2050022 | 0.83 | UCHL1 (0.57) | NPBWR1MCHR1UCHL1 | |
| SCHEMBL20916894 | 0.83 | TSHR (0.48) | CCR2KDM5AKDM4CKDM5B | |
| SCHEMBL1048024 | 0.82 | NPBWR1 (0.48) | NPBWR1MCHR1CYP19A1UCHL1 | |
| SCHEMBL14368129 | 0.81 | PTGER4 (0.59) | NPBWR1 | |
| SCHEMBL17869333 | 0.81 | GRN (0.51) | CCR2CYP19A1 | |
| SCHEMBL13724241 | 0.80 | NPBWR1 (0.56) | NPBWR1MCHR1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181205-A | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-102822170-B | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2014-12-10 | — | — | CN | disclosed |
| US-8513252-B2 | Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2456769-B1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-06-26 | — | — | EP | disclosed |
| CN-102822170-A | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC | 2012-12-12 | — | — | CN | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| CN-1578660-B | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | BRISTOL MYERS SQUIBB CO | 2010-11-24 | — | — | CN | disclosed |
| CN-1578660-A | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM1, GRM4, GRM3 | NPBWR1 476/4885CCR2 1820/4885MCHR1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.